oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 25 and Orforglipron for Obesity: New Insights ECO 2026 - OASIS 4:

Real-World Results and Expectations Timeline of Expected Results Realistic expectations for Tesamorelin/Ipamorelin therapy: Weeks 1-2: Improved sleep quality Better recovery from workouts Slight increase in energy Possible initial water retention Weeks 3-6: Noticeable improvements in body composition Reduced visceral fat (waist measurements) Enhanced skin quality and appearance Increased muscle fullness Better mood and mental clarity Weeks 7-12: Significant fat loss (especially abdominal) Visible muscle definition improvements Enhanced exercise performance Improved metabolic markers Better overall sense of wellbeing Beyond 12 weeks: Continued body composition improvements Sustained metabolic benefits Long-term anti-aging effects Maintained muscle mass during fat loss Typical Results by Goal Fat loss focus: 5-15 pounds fat loss over 12 weeks 1-3 inch waist circumference reduction Improved visceral fat measurements Better insulin sensitivity Body recomposition: 3-8 pounds fat loss 2-5 pounds lean muscle gain Improved muscle-to-fat ratio Enhanced muscle definition Anti-aging and wellness: Improved skin elasticity and appearance Better sleep quality scores Enhanced recovery metrics Improved energy and vitality Better metabolic health markers "The Tesamorelin/Ipamorelin blend has been a game-changer for clients over 40 who struggle with stubborn abdominal fat despite proper diet and exercise

A pooled analysis published in the National Institutes of Health PMC archive found tirzepatide reduced body weight more than semaglutide across different study designs, and a journal review summarized by the American College of Cardiology reported significantly greater weight loss with tirzepatide

Instead of managing multiple vendor relationships, organizations are looking for one accountable partner that can coordinate care across lifestyle, medication, behavioral support, and surgical pathways

The patient was subsequently transferred to the hospitals rehabilitation unit and discharged home after 30 days of hospitalization (Figure 2)

SELENOP: selenoprotein P